{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-073130","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.313677+00:00","generated_at":"2026-05-17T17:32:45.590726+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Relmada reports Q2 net loss $9.9M; NDV-01 91% overall response rate in NMIBC","bullets":["Q2 net loss $9.9M ($0.30/shr) vs $17.8M ($0.59) a year ago; R&D expense fell to $2.8M from $10.7M.","NDV-01 Phase 2: 91% complete response at any time; 90% at 6 months; no Grade 3+ TRAEs or discontinuations.","Cash $20.6M at June 30, 2025, down from $44.9M at Dec 31, 2024; shares outstanding 33.2M.","Phase 3 registration trial for NDV-01 planned for 1H 2026; Phase 2 for sepranolone in PWS in 1H 2026.","No patients progressed to muscle-invasive disease or underwent cystectomy in the study."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-073130","json":"https://secwatch.observer/filing/0001213900-25-073130.json","markdown":"https://secwatch.observer/filing/0001213900-25-073130.md","text":"https://secwatch.observer/filing/0001213900-25-073130.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025073130/0001213900-25-073130-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025073130/ea0252310-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:32:45.590726+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}